Auro Pharma, a subsidiary of Aurobindo Pharma, has acquired Khandelwal Laboratories' non-oncology prescription formulations business for Rs 325 crore in a cash deal. The transaction, effective January 1, includes 23 brands and nine pipeline products, primarily in anti-infective and pain management segments. This acquisition aims to expand Aurobindo Pharma's domestic market presence and complement its existing product portfolios. No government or regulatory approvals were required for the deal.